

Isotretinoin Restrictions Eased for Select Patients

BY HEIDI SPLETE
Senior Writer

Women who have no chance of becoming pregnant, as well as men, no longer need to observe a 23-day lockout period before starting a new prescription of isotretinoin for the treatment of acne, according to a statement from the Food and Drug Administration.

To take advantage of this change, however, patients must repeat the qualification

process to confirm that they meet the qualifying criteria to skip the 23-day lockout.

The iPLEDGE program was designed as a risk management plan to prevent, because of its severe teratogenic side effects, the use of isotretinoin by females who are or may become pregnant. The program initiated a universal set of strict criteria to be met before any patients could receive isotretinoin, regardless of their childbearing potential.

According to the original criteria, all female patients who wanted to take

isotretinoin had to undergo a pregnancy test, and all patients had to be counseled that two types of contraception are essential while taking isotretinoin.

Once these criteria were met, patients had 7 days to fill a prescription. If they didn't fill it within that time, they would have to wait for 23 days, a time frame designed to accommodate another pregnancy test for women who could become pregnant. This process was to be repeated for each refill, which increased

the administrative workload for clinicians and put pressure on patients.

Since then, clinicians' frustration with the iPLEDGE criteria has led to efforts by the American Academy of Dermatology and other organizations to convince the FDA and drug manufacturers that iPLEDGE needed revision.

For more information about the changes to the iPLEDGE program, visit the Web site at www.ipledgeprogram.com or call iPLEDGE at 1-866-495-0654. ■

Start and stay with nonscheduled Rozerem— ZERO evidence of abuse or dependence

Clinical studies show no evidence
of potential abuse, dependence, or withdrawal*

- **First and only**—nonscheduled prescription insomnia medication... not a controlled substance and approved for long-term use¹
- **First and only**—prescription insomnia medication that targets the normal sleep-wake cycle¹
- **First and only**—prescription insomnia medication with no evidence of abuse potential in clinical studies¹
- **First and only**—prescription insomnia medication that does not promote sleep by CNS depression¹
- **Promote sleep with Rozerem**—patients who took Rozerem fell asleep faster than those who took placebo¹
- **One simple 8-mg dose**¹

*Rozerem is not a controlled substance. A clinical abuse liability study showed no differences indicative of abuse potential between Rozerem and placebo at doses up to 20 times the recommended dose (N=14). Three 35-day insomnia studies showed no evidence of rebound insomnia or withdrawal symptoms with Rozerem compared to placebo (N=2082).^{1,2}

Please visit www.rozerem.com

 **Rozerem**TM
ramelteon 8-mg tablets

*Proven for sleep.
Nonscheduled for added safety.*